Skip to main content
S&P 5007,592.40-0.35%DOW52,297.09-0.36%NASDAQ25,366.09-0.39%BTC$69,215.00-4.86%ETH$1,957.59-3.01%GOLD$3,898.50+0.34%OIL$88.62-0.14%
Smart Investors Daily
SID Premium
RE

NASDAQ · REPL

Replimune Group, Inc.

Healthcare · Biotechnology

$21.98

Up+$0.20 (+0.92%)

Updated Nov 13, 2026, 12:24 PM

SID Score

6.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
774.6M
P/E ratio
-3.23
Dividend yield
0.00%
52-week range
$1.50 – $23.54
Volume
2.89M
Avg. volume
5.08M

Price performance · REPL

REPL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 12, 2026

REPL closed at $21.98 after 21 trading sessions, up 87.06% for the selected period.

Last close
$21.98
Period change
+87.06%
Period low
$10.86
Period high
$23.28
Daily close
View OHLC price history
REPL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 12, 2026$21.32$22.10$20.48$21.982.89M
Nov 11, 2026$23.54$23.54$21.74$21.783.03M
Nov 10, 2026$22.10$23.41$22.00$23.283.02M
Nov 9, 2026$21.90$22.72$21.75$22.263.2M
Nov 6, 2026$20.20$21.91$20.20$21.622.98M
Nov 5, 2026$20.57$20.59$19.33$20.024M
Nov 4, 2026$20.80$21.15$20.2101$20.693.22M
Nov 3, 2026$19.52$21.2599$19.50$20.654.73M
Nov 2, 2026$17.75$19.675$17.67$19.497.73M
Oct 30, 2026$17.49$18.2735$16.635$17.613.85M
Oct 29, 2026$16.27$17.78$16.195$17.395.15M
Oct 28, 2026$12.96$16.75$12.50$16.067.28M
Oct 27, 2026$12.45$13.16$12.2065$13.054.3M
Oct 26, 2026$11.56$12.57$11.36$12.472.05M
Oct 23, 2026$11.92$11.92$11.43$11.461.91M
Oct 22, 2026$11.70$12.01$11.5293$11.991.76M
Oct 21, 2026$11.37$12.045$11.31$11.722.2M
Oct 20, 2026$11.04$11.69$10.995$11.421.39M
Oct 19, 2026$11.03$11.225$10.67$11.051.54M
Oct 16, 2026$11.73$11.73$10.805$10.861.71M
Oct 15, 2026$11.32$11.86$11.2314$11.751.61M

Latest REPL news

The latest Smart Investors Daily articles mentioning REPL.

Stock researchCompany · Overview

REPL research

Overview

Company profile and research snapshot.

Company profile

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.67
Implied upside
—
Analysts
—
REPL recent ratings
DateFirmRatingTarget
Oct 29, 2026Leerink PartnersOutperform—
Aug 26, 2026JP MorganOverweight—
Aug 7, 2026JP MorganOverweight—
Aug 7, 2026WedbushOutperform—
Aug 4, 2026Leerink PartnersOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 5, 2026

How Investors May Respond To Replimune Group (REPL) Narrower Quarterly Loss

Replimune Group reported second quarter 2026 results with a net loss of US$57.12 million and basic loss per share of US$0.54, both lower than the prior year, and a six month net loss of US$126.89 million with US$1.26 loss per share. The reduced losses suggest tighter cost control or timing of spending as Replimune Group shifts from pure development toward commercialisation of its oncolytic immunotherapy portfolio. We will look at how Replimune Group's narrower quarterly net loss shapes the...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By